1. Home
  2. LNZA vs TENX Comparison

LNZA vs TENX Comparison

Compare LNZA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LanzaTech Global Inc.

LNZA

LanzaTech Global Inc.

N/A

Current Price

$6.32

Market Cap

61.2M

Sector

Industrials

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.74

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNZA
TENX
Founded
2005
1967
Country
United States
United States
Employees
N/A
16
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.2M
71.1M
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
LNZA
TENX
Price
$6.32
$1.74
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$14.00
$29.67
AVG Volume (30 Days)
62.4K
8.0M
Earning Date
05-18-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
17.00
N/A
Revenue
$55,845,000.00
N/A
Revenue This Year
$55.80
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.37
N/A
Revenue Growth
12.61
N/A
52 Week Low
$5.02
$1.31
52 Week High
$44.00
$19.40

Technical Indicators

Market Signals
Indicator
LNZA
TENX
Relative Strength Index (RSI) 51.85 19.00
Support Level $5.38 $1.31
Resistance Level $6.50 $16.39
Average True Range (ATR) 0.42 0.45
MACD 0.07 -0.59
Stochastic Oscillator 61.96 3.34

Price Performance

Historical Comparison
LNZA
TENX

About LNZA LanzaTech Global Inc.

LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: